Type IV gastric NET, the one associated with PPIs... More data pointing to a subset of gastric NETs associated with long-term PPI use, often called type IV. Compared to type III, type IV is much more indolent and less likely to metastasize. sciencedirect.com/science/articl…

The results of the COMPETE trial (LU-177 DOTATOC vs. everolimus is mostly second line therapy (small subset 1st line). Radioligand therapy superior to everolimus. #ESMO25 Jaume Capdevila

#ESMO25 Pegfilgrastim timing matters! In this randomized phase III trial (n=159, early-stage BC): Giving pegfilgrastim 72h after chemo — instead of 24–48h — cut bone pain by >50% without increasing neutropenia or FN risk.

TALENTop phs 3: Liver resection versus continued atezolizumab plus bevacizumab in locally advanced HCC after atezo/bev treatment #ESMO25 #ESMOAmbassadors 👉 EFS: 11 vs vs 20 mo 🧐great study design: response adapted subsequent therapy. Multimodal therapy in HCC is key @myesmo

Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX in Resectable, High-Risk iCCCA: Phase II-III Trial #ESMO25 #ESMOAmbassadors 👉 EFS: 8 vs 18mo 🧐Strong signal for neoadjuvant therapy in BTC, more trials to come.. @myesmo

STELLAR-303 lights up the refractory CRC space 🌌🧬 OncoAlert For the first time, an IO-based regimen shows an OS benefit in microsatellite-stable (MSS) metastatic CRC — a setting long resistant to immunotherapy. STELLAR-303 compared zanzalintinib + atezolizumab vs

👑DYNAMIC-III ctDNA(-) cohort Presidential 3 #ESMO25 ESMO - Eur. Oncology ➡️ctDNA-guided adjuvant ChT de-escalation in stage-III colon cancer ✅de-escalation may be non-inferior in clinical low-risk (T1-3N1) tumours #cancer #oncology #MedX OncoAlert

RT for massive HCC. In series (n=156) w median tumor size 12.9 cm, local control w RT (+/- opt'l TACE) = 86%. RT dose modest (4Gy x 6-10 fx): HCC is radiosensitive. Recall in RTOG 1112, med size 7.8 cm. IMO among local HCC tx, RT/SBRT has strongest evidence for larger tumors.

Holy smokes. Amazed to be in the company of Arndt Vogel and Erman Akkus ! Looking forward to keep shining a critical eye towards #GIOnc. Really excited with all the progress that is being made. Thanks LARVOL

Review: TNT in LAGEA — Rethink Paradigm 💡 All systemic tx pre-surgery 📈 pCR: top DFS/OS predictor ✅ >90% complete NAC vs ~50% adjuvant 🔥 D-FLOT: pCR 19% vs 7% (MATTERHORN) 💪 6–8 cycles feasible in fit pts ➡️ Prioritize effective tx upfront. 🔗 doi.org/10.1200/OA-25-…

ESMO–ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors sciencedirect.com/science/articl… ESMO - Eur. Oncology ESTRO

We at Mayo Clinic Comprehensive Cancer Center were visited by a true giant in the field of oncology today. None other than Dr. Lawrence Einhorn. A riveting talk, mostly focused on testis cancer as expected but lots of other goodies in there too. The final slide, a quote from H. G. Wells is very fitting.

DPYD testing is back in the news for Capecitabine and 5FU! What to do and how to dose reduce if you see an intermediate or poor metabolizer? #gism #OncTwitter #MedTwitter #bcsm

The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. The limitations of biopsy have led to the development of noninvasive tests, which Drs. Laurent Castera, Mary E. Rinella, and Emmanuel A. Tsochatzis review.

❓Is multifocal intrahepatic cholangiocarcinoma really stage-II? HEPATOLOGY Journal ➡️Within stage II, multifocal ➡️ 🔻OS than solitary 🚨Similar prognosis with satellite lesions and intrahepatic metastasis 🚨Multifocal stage II ➡️ similar prognosis with stage III

The weekly cancer MDT meeting can cause treatment delays, result in poor quality decisions, and waste clinicians’ time, say Tom Roques and colleagues. As cancer incidence continues to rise, MDT meetings on cancer must be overhauled bmj.com/content/391/bm…

Analysis of SANO shows: 1) Only 11% of cN2-3 pts had sustained cCR 2) No reliable baseline predictors of cCR IMO surveillance if cCR to CROSS still worth discussion, but caution if cN2-3, & intensive multimodal reassessment needed in absence of better biomarkers. OncoAlert

📗Adrenocortical carcinoma: a practical guide for clinicians The Lancet Diabetes & Endocrinology ✅Very nice source for practice ✅Diagnosis, treatment algorithm, systemic treatment, mitotan management 👉thelancet.com/journals/landi… #cancer #oncology #MedX OncoAlert

Big day for a rare disease 🎉🧬 The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer”

Our framework for navigating local therapy options in HCC. With Riad Salem. Table below & details in #ASCODailyNews article. Recs take into account global practice patterns, tech availability, guidelines, etc. Always open to feedback🙂. dailynews.ascopubs.org/do/navigating-… OncoAlert